These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35857858)

  • 1. Tazarotene Lotion 0.045% for the Treatment of Acne.
    Zip C
    Skin Therapy Lett; 2022 Jul; 27(4):1-3. PubMed ID: 35857858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
    Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
    J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.
    Kircik LH; Green L; Guenin E; Khalid W; Alexander B
    J Dermatolog Treat; 2022 Jun; 33(4):2241-2249. PubMed ID: 34459694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris.
    Kircik L
    J Drugs Dermatol; 2022 Jul; 21(7):713-716. PubMed ID: 35816073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
    Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
    J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
    Cook-Bolden FE; Gold MH; Guenin E
    J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups.
    Stein Gold L; Kircik L; Baldwin H; Callender V; Tanghetti E; Del Rosso J; Zeichner J; Cook-Bolden F; Guenin E
    J Drugs Dermatol; 2022 Jun; 21(6):587-595. PubMed ID: 35674760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tazarotene 0.045% Lotion: A Novel Retinoid Formulation.
    Mohney LA; Singh R; Feldman SR
    Ann Pharmacother; 2022 Oct; 56(10):1174-1180. PubMed ID: 35112585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tazarotene foam, 0.1%, for the treatment of acne.
    Smith JA; Narahari S; Hill D; Feldman SR
    Expert Opin Drug Saf; 2016 Jan; 15(1):99-103. PubMed ID: 26560170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
    Leyden JJ
    Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical Retinoids in Acne Vulgaris: A Systematic Review.
    Kolli SS; Pecone D; Pona A; Cline A; Feldman SR
    Am J Clin Dermatol; 2019 Jun; 20(3):345-365. PubMed ID: 30674002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.
    Tanghetti EA; Zeichner JA; Gold M; Sadick N; Cook-Bolden FE; Kircik LH; Stein Gold L; Weiss J; Tyring SK; Del Rosso JQ; Guenin E
    J Dermatolog Treat; 2023 Dec; 34(1):2147391. PubMed ID: 36382987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
    Tanghetti EA; Werschler WP; Lain E; Guenin E; Harris S; Loncaric A; Pillai R
    J Drugs Dermatol; 2020 Mar; 19(3):272-279. PubMed ID: 32549090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies.
    Draelos ZD
    J Dermatolog Treat; 2023 Dec; 34(1):2166346. PubMed ID: 36622889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations.
    Issa N; Kircik L
    J Drugs Dermatol; 2023 Jan; 22(1):3446174-34461710. PubMed ID: 36607764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
    Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
    J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
    Tanghetti E; Abramovits W; Solomon B; Loven K; Shalita A
    J Drugs Dermatol; 2006 Mar; 5(3):256-61. PubMed ID: 16573259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
    Eichenfield LF; Tanghetti EA; Guenin E; Martin G; Pillai R
    J Drugs Dermatol; 2020 Jun; 19(6):602-610. PubMed ID: 32574011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of Topical Retinoids: Are There Clinically Meaningful Differences Among Topical Retinoids?
    Culp L; Moradi Tuchayi S; Alinia H; Feldman SR
    J Cutan Med Surg; 2015; 19(6):530-8. PubMed ID: 26088502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.